GI CANCERS

Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.

Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting lower efficacy and increased toxicity.

Akeso initiates a pivotal trial for cadonilimab and lenvatinib, targeting advanced liver cancer resistant to PD-1 therapy, addressing urgent treatment needs.

Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.

Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, enhancing response rates significantly.

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting unmet clinical needs.

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining treatment standards.

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic pancreatic cancer patients.

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.

Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments for diseases like colon cancer.

Benjamin Schlechter, MD, discusses the safety and efficacy findings from the C-800-01 phase 1 trial evaluating botensilimab and balstilimab in colorectal cancer.

Verastem Oncology's VS-7375 receives FDA fast track designation, offering hope for targeted treatment in KRAS G12D-mutated pancreatic cancer.

Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for various cancers.

Benjamin Schlechter, MD, discusses the unmet needs and treatment gaps for patients with colorectal cancer.

Arturo Loaiza-Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into oncology.

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits in hard-to-treat cancers.

Agenus reveals promising survival rates for its immunotherapy in metastatic colorectal cancer, potentially transforming treatment for resistant patients.

Adcentrx Therapeutics advances gastric cancer treatment with FDA orphan drug designation for ADRX-0405, a promising antibody-drug conjugate in clinical trials.

Breelyn Wilky, MD, discusses what precision oncology advancements will most impact gastrointestinal stromal tumor management in the next 3 to 5 years.

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive malignancy.